Cargando…

The application of anticoagulant therapy to sepsis

Since the withdrawal of recombinant-activated protein C, the anticoagulant therapy for sepsis was taken no notice. For instance, the international sepsis guidelines did not share a space for this therapy. However, we can see the signs of change recently. The Surviving Sepsis Campaign Guidelines 2016...

Descripción completa

Detalles Bibliográficos
Autores principales: Thachil, Jecko, Iba, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450244/
https://www.ncbi.nlm.nih.gov/pubmed/28572981
http://dx.doi.org/10.1186/s40560-017-0230-3
_version_ 1783239930547273728
author Thachil, Jecko
Iba, Toshiaki
author_facet Thachil, Jecko
Iba, Toshiaki
author_sort Thachil, Jecko
collection PubMed
description Since the withdrawal of recombinant-activated protein C, the anticoagulant therapy for sepsis was taken no notice. For instance, the international sepsis guidelines did not share a space for this therapy. However, we can see the signs of change recently. The Surviving Sepsis Campaign Guidelines 2016 introduced the development of recombinant thrombomodulin, and the European Society of Intensive Care Medicine released comments on this subject. However, since small but important discrepancy was recognized between the standpoints of Japan (more aggressive) and other countries (rather conservative), we intend to discuss on this point.
format Online
Article
Text
id pubmed-5450244
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54502442017-06-01 The application of anticoagulant therapy to sepsis Thachil, Jecko Iba, Toshiaki J Intensive Care Letter to the Editor Since the withdrawal of recombinant-activated protein C, the anticoagulant therapy for sepsis was taken no notice. For instance, the international sepsis guidelines did not share a space for this therapy. However, we can see the signs of change recently. The Surviving Sepsis Campaign Guidelines 2016 introduced the development of recombinant thrombomodulin, and the European Society of Intensive Care Medicine released comments on this subject. However, since small but important discrepancy was recognized between the standpoints of Japan (more aggressive) and other countries (rather conservative), we intend to discuss on this point. BioMed Central 2017-05-30 /pmc/articles/PMC5450244/ /pubmed/28572981 http://dx.doi.org/10.1186/s40560-017-0230-3 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Thachil, Jecko
Iba, Toshiaki
The application of anticoagulant therapy to sepsis
title The application of anticoagulant therapy to sepsis
title_full The application of anticoagulant therapy to sepsis
title_fullStr The application of anticoagulant therapy to sepsis
title_full_unstemmed The application of anticoagulant therapy to sepsis
title_short The application of anticoagulant therapy to sepsis
title_sort application of anticoagulant therapy to sepsis
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450244/
https://www.ncbi.nlm.nih.gov/pubmed/28572981
http://dx.doi.org/10.1186/s40560-017-0230-3
work_keys_str_mv AT thachiljecko theapplicationofanticoagulanttherapytosepsis
AT ibatoshiaki theapplicationofanticoagulanttherapytosepsis
AT thachiljecko applicationofanticoagulanttherapytosepsis
AT ibatoshiaki applicationofanticoagulanttherapytosepsis